| Vol. 6.27 – 9 August, 2021 |
| |
|
|
| To explore the key extracellular matrix (ECM) proteins in the maintenance of the contractile phenotype of vascular smooth muscle cells (VSMCs), researchers applied protein-protein interaction network analysis to explore novel ECM proteins associated with the VSMC phenotype. [Circulation] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists generated sensorimotor organoids containing physiologically functional neuromuscular junctions and applied the model to different subgroups of amyotrophic lateral sclerosis. [Nature Communications] |
|
|
|
| The authors developed perturbation panel profiling as a framework for perturbing cells across many conditions and measuring gene expression responsiveness transcriptome-wide. [Cell Systems] |
|
|
|
| Investigators screened a library of 1280 bioactive compounds and identified those with potential cardiotoxic liabilities in induced pluripotent stem cell-cardiomyocytes using a single-parameter score based on deep learning. [eLife] |
|
|
|
| Single-cell RNA sequencing was performed with human induced pluripotent stem cell-derived cardiomyocytes and endothelial cells in mono- and co-culture. [Frontiers in Cell and Developmental Biology] |
| |
|
|
| Researchers provided preclinical characterization of an antagomiR-218 molecule using the HSALR mouse model and patient-derived myotubes. [Molecular Therapy-Nucleic Acids] |
|
|
|
| Scientists generated human-induced pluripotent stem cells depleted in MBNL proteins and evaluated the consequences of their losses on the generation of skeletal muscle cells. [Human Molecular Genetics] |
|
|
|
| Using wild type, AUF1 knockout mice and cultured myoblasts, AUF1 supplementation of muscle fibers was found to increase expression of PGC1α, a major effector of skeletal muscle mitochondrial oxidative metabolism. [Molecular Therapy-Methods & Clinical Development] |
|
|
|
| Comparing new-born with the other age groups, miR-10b, miR-126-5p, miR-143 and miR-146b were significantly up-regulated, whereas miR-21-5p, miR-221, miR-223 and miR-30b-5p were significantly down-regulated. [Scientific Reports] |
| |
|
|
| The authors harnessed CRISPR-Cas9 gene editing technology to introduce a mutation at cysteine 277 in the active site of the mouse Tgm2 gene. In vitro, a remodeling stimulus led to the significant loss of vascular compliance in wild-type mice, but not in the Tgm2-C277S or TG2−/− mice. [Cell Death Discovery] |
|
|
|
| Fluorescently labeled NLRP3 inflammasome particles were isolated from a mutant NLRP3-YFP cell line and used to treat primary human coronary artery smooth muscle cells for 4 and 24 hours. [Scientific Reports] |
|
|
|
| Researchers studied the possible role and mechanism of AMOTL2 in regulating transforming growth factor-β1-induced proliferation and extracellular matrix deposition of airway smooth muscle cells. [Environmental Toxicology] |
|
|
|
|
| Myocardial ischemia or reperfusion increases the generation of reactive oxygen species from damaged mitochondria, NADPH oxidases, xanthine oxidase, and inflammation. [Trends in Pharmacological Sciences] |
|
|
|
| The authors review the emerging contribution of fibro-adipogenic progenitors to skeletal muscle responses to motor neuron injuries and to systemic physiological or pathological metabolic perturbations. [Seminars in Cell & Developmental Biology] |
|
|
|
|
| Avidity Biosciences, Inc. announced that the US FDA cleared the company to proceed with the Phase I/II MARINAâ„¢ clinical trial of AOC 1001 in adults with DM1. AOC 1001 is designed to address the root cause of DM1 by reducing levels of DMPK, the disease-related mRNA. [Avidity Biosciences, Inc.] |
|
|
|
| PharmaTher Holdings Ltd. announced that the FDA has granted orphan drug designation for ketamine in the treatment of Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease. [PharmaTher Holdings Ltd.] |
|
|
|
|
| November 29 – December 1, 2021 Barcelona, Spain |
|
|
|
|
|
| Buck Institute for Research on Aging – Novato, California, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Weill Cornell Medicine – New York, New York, United States |
|
|
|
| The Scripps Research Institute – La Jolla, California, United States |
|
|
|
| Pompeu Fabra University – Barcelona, Spain |
|
|
|
|